On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53

Michal Bista, David Smithson, Aleksandra Pecak, Gabriella Salinas, Katarzyna Pustelny, Jaeki Min, Artur Pirog, Kristin Finch, Michal Zdzalik, Brett Waddell, Benedykt Wladyka, Sylwia Kedracka-Krok, Michael A. Dyer, Grzegorz Dubin, R. Kiplin Guy

Research output: Contribution to journalArticlepeer-review

45 Citations (SciVal)

Abstract

SJ-172550 (1) was previously discovered in a biochemical high throughput screen for inhibitors of the interaction of MDMX and p53 and characterized as a reversible inhibitor (J. Biol. Chem. 2010; 285:10786). Further study of the biochemical mode of action of 1 has shown that it acts through a complicated mechanism in which the compound forms a covalent but reversible complex with MDMX and locks MDMX into a conformation that is unable to bind p53. The relative stability of this complex is influenced by many factors including the reducing potential of the media, the presence of aggregates, and other factors that influence the conformational stability of the protein. This complex mechanism of action hinders the further development of compound 1 as a selective MDMX inhibitor.

Original languageEnglish
Article numbere37518
JournalPLoS ONE
Volume7
Issue number6
DOIs
StatePublished - Jun 4 2012

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53'. Together they form a unique fingerprint.

Cite this